Baili Tianheng (688506.SH): Injectable T-Bren (HER2 ADC) clinical trial completed the first patient enrollment

Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the innovative biopharmaceutical T-Bren (HER2 ADC) independently developed by the company has recently completed the first phase III randomized controlled clinical trial comparing T-Bren with doctor-selected chemotherapy in patients with locally advanced or metastatic biliary tract cancer with HER2 expression who failed to be treated with platinum-containing chemotherapy.

According to reports, T-Bren (BL-M07D1) is an innovative ADC targeting HER2. It has best-in-class (best-in-class) potential, and has shown significant anti-tumor efficacy in clinical trials. Up to now, T-Bren is conducting 19 clinical trials at home and abroad, including 8 phase III, 1 phase II/III, 4 phase I/II, and 3 phase I clinical trials, covering first-line and second-line HER2-positive breast cancer, HER2-positive breast cancer post-operative adjuvant treatment, HER2-positive breast cancer neoadjuvant treatment, HER2-positive breast cancer, HER2-positive gastric or gastroesophageal adenocarcinoma, HER2-positive gastric or gastroesophageal junction adenocarcinoma, HER2 mutant non-squamous non-small cell lung cancer, and HER2 positive platinum-containing failed biliary cancer, and lung cancer, gastrointestinal tumors, urination Multiple indications such as systemic tumors and gynecological tumors.